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Abstract Dural arteriovenous fistulae (DAVFs) are a rare
cause of intracranial haemorrhage. We aimed to investigate
outcome of patients with intracranial haemorrhage from a
DAVF. We performed a systematic literature search for
studies reporting outcome after intracranial haemorrhage
caused by a DAVF. We used predefined selection criteria
and assessed the quality of the studies. In addition, we
studied outcome in all patients with DAVF who had pre-
sented with intracranial haemorrhage at two university
centers in the Netherlands, between January 2007 and April
2012. We calculated case fatality and proportions of
patients with poor outcome (defined as modified Rankin
Scale C 3 or Glasgow Outcome Scale B 3) during follow-
up. We investigated mean age, sex, mid-year of study and
percentage of patients with parenchymal haemorrhage as
determinants of case fatality and poor outcome. The
literature search yielded 16 studies, all but two retrospec-
tive and all hospital-based. Combined with our cohort of 29
patients the total number of patients with DAVF-related
intracranial haemorrhage was 326 (58 % intracerebral
haemorrhage). At a median follow-up of 12 months case
fatality was 4.7 % (95 % CI 2.5–7.5; 17 cohorts) and the
proportion of patients with poor outcome 8.3 % (95 % CI
3.1–15.7; nine cohorts). We found no effect of mean age,
sex, mid-year of the cohorts and percentage of patients
with parenchymal haemorrhage on either outcome.
Hospital based case-series suggest a relatively low risk of
death and poor outcome in patients with intracranial
haemorrhage due to rupture of a DAVF. These risks may
be underestimated because of bias.
Keywords Dural arteriovenous fistula  Intracranial
haemorrhage  Outcome
Introduction
Dural arteriovenous fistulae (DAVFs) are rare vascular
lesions with a detection rate of 0.16/100,000 adults per year
[1]. They represent 10 to 15 % of all intracranial vascular
malformations [2]. About 20 % of patients with a DAVF
present with intracranial haemorrhage [1, 3], which is in
most patients associated with venous outflow from the
DAVF into a cortical vein (cortical venous reflux) [4–7].
Information on outcome after intracranial haemorrhage
due to a DAVF is limited due to the rarity of the lesions. In
patients with intracerebral haemorrhage (ICH) due to rup-
ture of an arteriovenous malformation (AVM), the risk of
poor outcome (modified Rankin Scale (mRS) C 3) is lower
than after spontaneous ICH, even after taking into account
predictors of outcome including age [8]. It is unclear
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whether outcome after ICH due to DAVF is similar to
outcome after a rupture of an AVM or comparable to
outcome after spontaneous ICH.
We aimed to investigate outcome after DAVF-related
intracranial haemorrhage by a systematic review of the
literature and studying a case-series in two tertiary referral
centers in the Netherlands.
Patients and methods
Systematic literature search
We performed a systematic literature search using PubMed
and Embase for studies of patients with a DAVF-related
intracranial haemorrhage from January 1980 to April 2015
(Supplementary Fig. 1) according to the PRISMA state-
ment methodology [9]. We used different combinations of
‘h(a)emorrhage’ or ‘hematoma’ and ‘dural arteriovenous
fistula’ and its synonyms (see Supplementary Table 1 for
details of the search strategy). References of included
articles, related citations and relevant reviews were
screened for additional articles. After filtering duplicates,
articles were screened by one reviewer (WMTJ) on title
and abstract using predefined inclusion and exclusion cri-
teria. Inclusion criteria were: (1) sample size of at least ten
patients with DAVF-related intracranial haemorrhage; (2)
the diagnosis of DAVF had to be proven by digital sub-
traction angiography in at least 90 % of patients; (3) fol-
low-up of at least one month; (4) if a study reported not
only patients with DAVF-related intracranial haemorrhage
but also other presenting symptoms, it had to be possible to
extract data on outcome for the patients with DAVF-related
intracranial haemorrhage separately. We excluded study
cohorts when more than 10 % of the fistulae were located
at the cavernous sinus, because these lesions have a
different etiology, more commonly a traumatic cause, a
mostly benign presentation, without intracranial haemor-
rhage, and a low rate of cortical venous reflux [10, 11]. We
defined a study as high quality based on predefined criteria,
namely, prospective, population-based, patients with
intracranial haemorrhage as inception cohort, and clearly
defined outcome measures (mRS or Glasgow Outcome
Scale (GOS)). Two investigators (WMTJ and CJJvA)
independently extracted data on study characteristics as
summarized in Table 1 and Supplementary Table 2. In
case of multiple publications from one cohort, we included
the most suitable publication. We defined poor outcome as
a mRS C 3 or GOS B 3. If a study used other outcome
measures, we extracted data on patients with poor outcome
or death according to the definition of the authors. Dis-
crepancies in extracted data between the two investigators
were dissolved by a third author (CJMK).
Cohort study
From the prospectively kept Utrecht Stroke Database,
including all patients with ischaemic stroke and intracere-
bral haemorrhage, and the Subarachnoid Haemorrhage
Database, we retrieved all patients with first DAVF-related
intracerebral (ICH), intraventricular (IVH) or subarachnoid
haemorrhage (SAH), who presented to the University
Medical Center Utrecht, the Netherlands, between January
2007 and April 2012. At the University Medical Center
Groningen we retrieved data on patients from a prospec-
tively kept neurovascular database, which we cross-
checked with patient discharge records. We retrieved data
on all patients with first DAVF-related intracranial haem-
orrhage who presented between January 2007 and January
2012.
For all patients baseline characteristics were collected as
listed in Supplementary Table 2. We reviewed imaging
Fig. 1 Case fatality with 95 %
CI after DAVF-related
intracranial haemorrhage
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studies for location and extension of haemorrhage (intrac-
erebral, subarachnoid, subdural or intraventricular, or a
combination of these) and location of the DAVF and we
classified DAVF’s according to Borden-Shucart (GAPdK
and JMCvD) [4]. The diagnosis of DAVF had to be proven
by digital subtraction angiography. For each patient with an
ICH we calculated the ICH score consisting of known
predictors of poor outcome after ICH [12]. The ICH score
is the sum of individual points assigned as follows: Glas-
gow Coma Scale (GCS) (3–4 = 2 points, 5–12 = 1 point,
13–15 = 0 points), age (C80 years = 1 point,\80 -
years = 0 points), infratentorial origin (yes = 1 point,
no = 0 points), ICH volume (C30 cm3 = 1
point,\30 cm3 = 0 points) and presence of IVH (yes = 1
point, no = 0 points). We calculated ICH volume (mL) on
brain imaging at presentation with the ABC/2 formula [13,
14]. In addition we retrieved information on death and poor
functional outcome after at least one month. We defined
poor outcome as a mRS C 3.
Statistical analysis
We calculated mean age, proportion of males, proportion
of patients with an intracerebral component of the haem-
orrhage, average intracerebral haemorrhage volume (for
patients with ICH), follow-up period, and proportion of
patients who died or had a poor outcome with corre-
sponding 95 % confidence intervals (CIs) during follow-up
of at least one month. In the cohort study we performed
univariate analysis of age, male sex, ICH vol-
ume[ 30 mL, and presence of a parenchymal component
of the haemorrhage for case fatality and poor outcome with
Cox proportional hazards analysis, resulting in hazard
ratios (HR) with 95 % CIs.
Proportions of patients with case fatality or poor out-
come were pooled using MedCalc for Windows, version
12.7 (MedCalc Software, Ostend, Belgium). Heterogeneity
between studies was calculated with the I2 statistic. To
investigate the association of mid-year of study, mean age,
percentage of males and percentage of patients with an
parenchymal component of the haemorrhage in the study
cohorts with the proportion of patients with case fatality or
poor outcome, we performed linear regression analysis
weighted by the inverse standard error.
Results
The literature search yielded sixteen studies that described
a total of 576 patients of whom 297 patients had a DAVF-
related intracranial haemorrhage (Table 1) [15–30]. Two
studies had a prospective design [20, 30]; all studies were
hospital-based, and none fulfilled all the criteria for high-
quality study. In all studies DAVFs were proven with
angiography in 100 % of patients.
Three studies described patients with haemorrhagic
presentation only [15, 26, 28], whereas all other studies
were not restricted to patients with ruptured DAVF, but
Table 1 Characteristics of cohorts of patients with DAVF-related intracranial haemorrhage
References Design Patients with DAVF-related
intracranial haemorrhage (n)
Duration of FU
(months, range)
Case fatality
(%, 95 % CI)
Poor outcome
(%, 95 % CI)
Duffau et al. [15] RS 20 10 (0.3–25) 15 (3.2–38) NR
Tomak et al. [16] RS 10 11.5 (1–123) 10 (0.3–45) 10 (0.3–45)
Van Rooij et al. [17] RS 18 1.5–3 0 (0–19) NR
Kakarla et al. [18] RS 22 12 (0–84) 0 (0–15) 0 (0–15)
Lawton et al. [19] RS 17 50 (1–108) 0 (0–20) 0 (0–20)
Cognard et al. [20] PS 16 3 6.3 (0.2–30) NR
Lv et al. [21] RS 16 8 (1–16) 0 (0–21) 0 (0–21)
Liu et al. [22] RS 13 45 (2–84) 0 (0–25) 0 (0–25)
Huang et al. [23] RS 12 3–24 8.3 (0.2–39) 8.3 (0.2–39)
Guedin et al. [24] RS 19 3–6 5.3 (0.1–26) NR
Wachter et al. [25] RS 16 50 (2–120) 0 (0–21) NR
Daniels et al. [26] RS 28 17 10.7 (2.3–28) 28.6 (13–49)
Eftekhar and Morgan [27] RS 15 18 (2–82) 6.7 (0.2–32) NR
Li et al. [28] RS 46 20 0 (0–8) 13 (5–26)
Chandra et al. [29] RS 13 28 (12–63) 0 (0–25) NR
Al-Mahfoudh et al. [30] PS 16 67 (24–102) 0 (0–21) NR
Jolink (2015) RS 29 5 (0–12) 10 (2.2–27) 14 (3.9–32)
CI confidence interval, DAVF dural arteriovenous fistula, FU follow-up, NR not reported specifically for patients with a DAVF presenting with
intracranial haemorrhage, PS prospective study design, RS retrospective study design
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rather descriptions of cohorts of patients with DAVF irre-
spective of their presenting symptoms or treatment. One
study described symptomatic DAVFs [16], ten studies
described DAVFs treated by a specific modality (surgery,
six studies [18, 19, 22, 25, 27, 30], endovascular treatment,
four studies [20, 21, 23, 29]), and two studies specifically
described patients with DAVFs with cortical venous reflux
[17, 24].
Four studies used the mRS [19, 21, 26, 28], three studies
the GOS [16, 18, 22] and one study described clinical
outcome in terms of excellent, good and death [23]. Eight
studies did not report on functional outcome. Information
concerning cortical venous reflux, ICH volume and ICH
score was not reported in most of the studies. Duration of
follow-up varied between studies (Table 1). In the case-
series, all patients with DAVF-related intracranial haem-
orrhage were included after their first haemorrhage; in two
studies, a total of eight patients had a rebleed before
treatment and outcome assessment [23, 28].
In the cohort study we included 29 patients; three
patients died during follow-up (Supplementary Table 2).
One patient (3 %) had a Borden–Shucart type 1 lesion, nine
patients (31 %) a type 2 lesion and 19 patients (66 %) a
type 3 DAVF. Eighteen patients presented with intracere-
bral haemorrhage. ICH volumes ranged between 0.2 and
46 ml. Five patients had an ICH score of 0 (28 %), six of 1
(33 %), three of 2 (17 %), three patients had an ICH score
of 3 (17 %) and one patient of 4 (6 %). During follow-up
none of the patients with an ICH score of 0, 1 or 2 died.
One patient with an ICH score of 3 and one patient with an
ICH score of 4 died. Two patients with an intracerebral
haemorrhage had a poor functional outcome (both patients
died). Eleven patients presented with a SAH or IVH or a
combination; one patient with a SAH died during follow-
up. Two patients with a SAH or IVH had a poor functional
outcome (one died and the other had a mRS of 3).
We found no associations with case fatality for age (HR
1.2, 95 % CI 0.96–1.4), male sex (HR 0.4, 95 % CI
0.03–3.9), ICH volume[ 30 mL (HR 6.1, 95 % CI
0.4–99.3), and a parenchymal component of the haemor-
rhage (HR 1.3, 95 % CI 0.1–14.3). We also found no
associations for poor outcome (data not shown).
Combining the data from the literature search and our
series, we had information on 326 patients with a DAVF-
related intracranial haemorrhage. The median age in all
study cohorts, including our own, was 54 years (in-
terquartile range (IQR) 51–59 years). The median propor-
tion of men was 73 % (IQR 63–84 %). Eleven studies with
a total of 246 patients reported the location of the
intracranial haemorrhage: ICH 161 (58 %), SAH 69
(25 %), SDH 16 (6 %), IVH 31 (11 %). In 31 patients the
haemorrhage was located in two or more of these
compartments.
Treatment modality was not reported specifically for
patients with DAVF-related intracranial haemorrhage in
most studies. In the total group of 567 patients included in
the studies, a total of 556 treatments was performed during
follow-up: 388 patients underwent endovascular treatment,
287 patients surgery, 13 patients radiosurgery and 132
patients received multiple treatment modalities. Eleven
patients were not treated at all.
Median follow-up for all patients was 12 months (IQR
7–37 months). In the five studies that specified the duration
of follow-up specifically for patients with intracranial
haemorrhage [15, 23, 26, 28], the median duration of fol-
low-up was 10 months (IQR 6–19 months). The proportion
of patients lost to follow-up varied from 0 % to 27 %.
Case fatality after DAVF-related haemorrhage was
4.7 % (95 % CI 2.5–7.5, 17 cohorts, Fig. 1) [15–30] and the
proportion of patients with poor outcome 8.3 % (95 % CI
3.1–15.7; 9 cohorts; Fig. 2) [16, 18, 19, 21–23, 26, 28]. We
did not find a statistically significant effect on case fatality
for mid-year of the study (b-0.3, 95 % CI-0.8 to 0.2), for
mean age (b 0.2, 95 % CI -0.4 to 0.7), for percentage of
males (b 0.04, (95 % CI -0.2 to 0.3) or for percentage of
patients with an intracerebral component of the intracranial
haemorrhage (b -0.1 (95 % CI -0.2 to 0.1). In addition, we
found no effect on poor outcome (mid-year of study b 0.4,
95 % CI -1.1 to 2.0; mean age b 0.4, 95 % CI -1.1 to 2.0;
percentage of males b 0.4,95 % CI -0.3 to 1.1; percentage
of patients with an intracerebral component of the
intracranial haemorrhage b 0.1, 95 % CI -0.3 to 0.5).
Discussion
Hospital based case-series suggest a relatively low risk of
death and poor outcome in patients with intracranial
haemorrhage due to rupture of a DAVF. We found no
association of mid-year of studies, mean age, percentage of
males, or percentage of patients with an intracerebral
component of the haemorrhage with these outcomes.
In population-based cohorts, patients with an ICH due to
an AVM have a risk of death of 12 % after 6 months and of
poor outcome at one year of 40 % [8]. This risk is much
lower than the reported risk after spontaneous ICH with a
risk of death after 6 months of 56 % and of poor outcome
at 12 months of 83 % [8]. A possible reason why we found
lower estimates of the risk of death and poor outcome for
patients with intracranial haemorrhage due to a DAVF is
that the studies on which we based our estimates were all
hospital based and may therefore have been influenced by
referral bias, resulting in underestimation of the proportion
of patients with poor outcome. Another explanation may be
that in patients with a fatal or severely disabling intracra-
nial haemorrhage due to DAVF rupture, investigations to
J Neurol (2015) 262:2678–2683 2681
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determine the cause of the intracranial haemorrhage may
not always have been performed [31]. Also, DAVFs can be
missed on CTA or MRA [32]. A further explanation may
be that in contrast to the study that compared outcomes
after AVM and spontaneous ICH [8], the cohorts in our
study did not restrict inclusion to patients with ICH but
included patients with SAH, IVH and SDH as well.
A possibly better clinical outcome from DAVFs in
comparison with outcome after spontaneous or AVM-re-
lated ICH may be explained by the bleeding site of the
ruptured DAVF being venous rather than arterial [26].
Several studies showed that intracranial haemorrhage due
to a DAVF is related with cortical venous reflux, venous
hypertension and venous congestion [7, 33–35]. Location
of the DAVF-related haemorrhage being less often deep
may also explain a better clinical outcome [36].
A strength of our study is that by combining the cohorts
of two university medical centers and an overview of the
current literature, we were able to study a relatively large
number of patients given the rarity of this disease and study
determinants of outcome. Also, we included patients irre-
spective of whether they had been treated or not, avoiding
the selection mechanisms of some of the previous studies
[18–23, 25]. Our study also has limitations. Limitations of
our literature search are that none of the included studies
fulfilled all our criteria of high quality. Second, outcome in
the review includes the effects of treatment and is descri-
bed over varying durations of follow-up. Furthermore,
designs of included studies were heterogeneous, so results
need to be interpreted with caution. Third, studies were not
always restricted to patients who had presented with
intracranial haemorrhage. Ten of the sixteen cohorts
described patients treated by a specific modality, most
certainly resulting in selection by indication. Also, differ-
ent ways of reporting functional outcome were used.
Our study has implications for clinical practice. The
outcome after the rupture of a DAVF can be used to inform
patients and their relatives. Furthermore, our findings
should be taken into account when weighing risks and
benefits of treatment in patients with unruptured DAVFs.
Studies of large patient cohorts, preferably prospective and
population based, should give more precise estimates of the
risk of poor outcome after DAVF-related intracranial
haemorrhage and of factors that may determine outcome.
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